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Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354S348mcg/L (range: 32-263) 20 minutes post-CIS inhalation. Lung
deposition studies showed the total deposited dose averaged
13% (range: 4-20%) of the inhaled dose. Of note, 5 subjects
who showed a clinical beneﬁt on study were subsequently
enrolled onto a CIS extension protocol.
Conclusion: These data are the ﬁrst to establish that CIS is
safe and can stabilize or improve lung function in HSCT re-
cipients with severe BOS, allowing systemic immunosup-
pression to be reduced. Importantly, lung deposition studies
revealed substantial delivery of CIS could be achieved in the
airways with only minimal systemic absorption.
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Blocking Notch signaling after allogeneic bone marrow
transplantation prevents acute graft-versus-host disease
(GVHD) in mice, with key roles for Notch1/2 receptors and
Delta-like-1/4 ligands (Dll1/4) (Zhang, Blood 2011; Tran, JCI
2013). To investigate the consequences of Notch inhibition in
alloantigen-speciﬁc T cells, we identiﬁed a short 2-day win-
dow of Notch activity early after transplantation during
which Notch blockade is critical for maximal prevention of
acute GVHD. We describe new mechanistic models to study
alloantigen-speciﬁc T-cells within this window, and provide
insights into early events associated with Notch blockade. In
a MHC-mismatched model, transgenic C57Bl/6 CD4+ 4C T-
cells directly recognizing host I-Ad alloantigens induced le-
thal GVHD in BALB/c recipients. 4C CD4+ T-cells were sensi-
tive to Notch blockade, which resulted in the downregulation
of Notch target genes in and impaired production of in-
ﬂammatory cytokines, concordant with ﬁndings in poly-
clonal responses (Zhang, Blood 2011; Tran, JCI 2013).
Nonetheless, serial analysis revealed preserved 4C CD4+ T-
cell activation, proliferation and expansion upon Dll1/4
blockade. In the B10.D2/BALB/c MHC-matched model of
sclerodermatous GVHD, donor-derived CD4+Vb3+ T-cells,
responding to a Mtv6-encoded BALB/c superantigen,
demonstrated massive expansion and dominant Th1 polari-
zation of Vb3+ T-cells in lymphoid tissues and the liver.
Despite this, Notch blockade in Vb3+ T-cells inhibited cyto-
kine production, but preserved activation and proliferation.
These ﬁndings document dissociated effects of Notch inhi-
bition on proliferation and cytokine production in alloan-
tigen-speciﬁc T-cells, allowing further focused evaluation of
Notch signaling functions in alloimmunity.
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Purpose: Haplo-identical transplants are increasingly used
in hematopoietic stem cell transplantation (HSCT). Do haplo-
identical transplants have a stronger graft-versus-leukemia
(GVL) effect?
Patients and Methods:We analyzed 10,679 patients with
acute leukemia undergoing HSCT from an HLA-matched
sibling donor (MSD, n¼9,815), or a haplo-identical donor
(2 HLA-antigen disparity, n¼864) between 2007e2012,
reported to the European Group for Blood and Marrow
Transplantation. In a Cox regression model, acute and
chronic GVHD were added as time-dependent variables.
Results: In the multivariate analysis, there was no differ-
ence in relapse probability between recipients of haplo-
identical or MSD grafts. This was seen in T-cell replete and
T-cell depleted grafts analyzed separately. Factors of
importance for relapse among T-cell replete grafts included
remission status at HSCT, Karnofsky score 80, acute GVHD
grade II, and chronic GVHD (p<10-5). Among patients
receiving T-cell depleted grafts, advanced disease (p<10-5)
and second remission (p¼0.01) compared to ﬁrst remission
were the strongest factors for leukemic relapse. Non-
relapse mortality was signiﬁcantly higher in the haplo
group versus MSD transplants among patients receiving T-
cell repleted grafts or T-cell depleted grafts (p<10-5).
Subsequently, leukemia-free survival was superior in the
MSD group of T-cell replete grafts (p<10-5) and T-cell
depleted grafts (p¼0.0006).
Conclusion: Risk of relapse was the same in patients with
acute leukemia in haplo-identical transplant recipients
compared with MSD transplants, suggesting a similar
GVL effect.508
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Introduction: We describe a case of a 52-year-old man with
history of refractory angioimmunoblastic T-cell lymphoma
11months aftermatched unrelated allogeneic hematopoietic
cell transplant with acute ﬁbrinous organizing pneumonitis
successfully treated with high dose steroids, tacrolimus, and
8 doses of etanercept.
Case presentation: A 52-year-old Caucasian male with a
history of refractory stage IV angioimmunoblastic T-cell
lymphoma treated with CHOP, ICE and Romidepsin fol-
lowed by ATG/TBI matched unrelated allogeneic he-
matopoietic cell transplant (HCT) in March 2013. He had
an uncomplicated course with the exception of mild
classic chronic GVHD of skin treated with topical ste-
roids. Eleven months after HCT, he was off
